Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

ces with respect to the Company's clinical programs include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that preclinical data will indicate that urocortin 2 is not suitable for further clinical studies; risk that the CRF1 receptor antagonist candidate's Phase II proof of concept clinical studies will not support further clinical studies; and overall risk that the Company's clinical candidates will not proceed to later stage clinical trials. Risks associated with the Company's indiplon program include, but are not limited to, risk that indiplon approval and subsequent commercialization may be indefinitely delayed or never accomplished. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2007 and report on Form 10Q for the quarter ended June 30, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

NEUROCRINE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations

(in thousands, except for per share data)

Three Months Ended Nine Months Ended

September 30,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... RPS Diagnostics (RPS®) – a developer ... its third annual partnership of the Centers for ... Antibiotics Week from November 17-23. , Get Smart ... to highlight the coordinated efforts of CDC, state ... partners to provide education about the importance of ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Providerâ„¢ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
(Date:11/18/2014)... 2014 Array Architects is proud of ... to the nation's hospitals and health systems. It is ... dedicating their careers to the advancement of both the ... her respective field, Laura Silvoy has been chosen to ... Winter Simulation Conference. , Laura will present her ...
(Date:11/18/2014)... DOYLESTOWN, Pa. , Nov. 18, 2014  Novira ... therapies for curative treatment of chronic hepatitis B virus ... , M.D., was appointed to its Scientific Advisory Board ... Brian join our SAB," said Christian S. Schade ... wealth of clinical development experience which will be invaluable ...
Breaking Biology Technology:RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3
... Feb. 10 Microdosing or Phase 0 clinical ... an imperative phase of the drug development process ... niche capability providers in preclinical testing and technology ... partnerships and alliances, fuelling growth opportunities in this ...
... an MBA-student organized event, will be held February 19-20 in Philadelphia. ... from Healthcare Services, Investment, Pharma, Biotech, and Medical Device sectors. ... ... 2009 Wharton Health Care Business Conference , an MBA-student organized ...
... DSM Biologics and Crucell N.V. (Euronext, Nasdaq: ... they have entered into an agreement with Bioceros B.V. ... Under the terms of the agreement, Bioceros will be ... the PER.C6(R) cell line located in the European Union.Karen ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 314th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... DAVIS--Mosquito traps that reek like latrines may be no ... team led by chemical ecologist Walter Leal has discovered ... making humans hold their noses. The synthetic mixture, ... just as enticing to Culex mosquitoes as the current ...
... and South Africa have created a biophysical methodology ... potentially remedy even substantial hearing loss. The authors ... the ear to recognize frequencies originally associated with ... the open-access journal PLoS Computational Biology . ...
... Presenting new research about national, home and business security ... of Houston professor and his colleagues has become the ... to surveillance. Two professors and two ... Institute of Electrical and Electronics Engineers International Conference on ...
Cached Biology News:No more big stink: scent lures mosquitoes, but humans can't smell it 2Biophysical method may help to recover hearing 2National security remedies among topics at surveillance confab 2National security remedies among topics at surveillance confab 3
Request Info...
... 5B15-5B-11E. Immunogen: Synthetic peptide derived from ... protein. Specificity: Specific for the ... Western blots it identifies the target band ... (positive controls: deglycosylated secreted media from primary ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: